CRISPR Therapeutics AG [CRSP] Revenue clocked in at $77.40 million, up 99.57% YTD: Whats Next? – The DBT News
Posted: November 30, 2020 at 7:01 pm
CRISPR Therapeutics AG [NASDAQ: CRSP] jumped around 11.55 points on Friday, while shares priced at $121.55 at the close of the session, up 10.50%. The company report on November 24, 2020 that CRISPR Therapeutics to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference.
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, announced that members of its senior management team are scheduled to participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference on Wednesday, December 2, 2020, at 9:30 a.m. ET.
A live webcast of the event will be available on the Events & Presentations page in the Investors section of the Companys website at https://crisprtx.gcs-web.com/events. A replay of the webcast will be archived on the Companys website for 14 days following the presentation.
CRISPR Therapeutics AG stock is now 99.57% up from its year-to-date (YTD) trading value. CRSP Stock saw the intraday high of $124.43 and lowest of $110.355 per share. The companys 52-week high price is 111.90, which means current price is +276.32% above from all time high which was touched on 11/27/20.
Compared to the average trading volume of 903.62K shares, CRSP reached a trading volume of 1124305 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for CRSP shares is $102.63 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on CRSP stock is a recommendation set at 2.20. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
RBC Capital Mkts have made an estimate for CRISPR Therapeutics AG shares, keeping their opinion on the stock as Sector Perform, with their previous recommendation back on October 23, 2020. While these analysts kept the previous recommendation, BofA Securities raised their target price to Buy. The new note on the price target was released on October 05, 2020, representing the official price target for CRISPR Therapeutics AG stock. Previously, the target price had yet another raise from $84 to $105, while Needham kept a Buy rating on CRSP stock.
The Average True Range (ATR) for CRISPR Therapeutics AG is set at 5.67, with the Price to Sales ratio for CRSP stock in the period of the last 12 months amounting to 100.41. The Price to Book ratio for the last quarter was 6.35, with the Price to Cash per share for the same quarter was set at 21.36.
CRISPR Therapeutics AG [CRSP] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 11.27. With this latest performance, CRSP shares gained by 28.34% in over the last four-week period, additionally plugging by 82.53% over the last 6 months not to mention a rise of 78.46% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CRSP stock in for the last two-week period is set at 74.92, with the RSI for the last a single of trading hit 82.45, and the three-weeks RSI is set at 68.66 for CRISPR Therapeutics AG [CRSP]. The present Moving Average for the last 50 days of trading for this stock 96.86, while it was recorded at 112.25 for the last single week of trading, and 74.64 for the last 200 days.
Operating Margin for any stock indicates how profitable investing would be, and CRISPR Therapeutics AG [CRSP] shares currently have an operating margin of +16.14. CRISPR Therapeutics AGs Net Margin is presently recorded at +23.09.
Return on Total Capital for CRSP is now 6.75, given the latest momentum, and Return on Invested Capital for the company is 9.72. Return on Equity for this stock inclined to 10.04, with Return on Assets sitting at 8.59. When it comes to the capital structure of this company, CRISPR Therapeutics AG [CRSP] has a Total Debt to Total Equity ratio set at 5.59. Additionally, CRSP Total Debt to Total Capital is recorded at 5.30, with Total Debt to Total Assets ending up at 4.93. Long-Term Debt to Equity for the company is recorded at 4.69, with the Long-Term Debt to Total Capital now at 4.44.
Reflecting on the efficiency of the workforce at the company, CRISPR Therapeutics AG [CRSP] managed to generate an average of $219,928 per employee. Receivables Turnover for the company is 135.10 with a Total Asset Turnover recorded at a value of 0.37.CRISPR Therapeutics AGs liquidity data is similarly interesting compelling, with a Quick Ratio of 16.50 and a Current Ratio set at 16.50.
With the latest financial reports released by the company, CRISPR Therapeutics AG posted 0.51/share EPS, while the average EPS was predicted by analysts to be reported at -0.63/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 181.00%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for CRSP.
There are presently around $5,761 million, or 69.30% of CRSP stock, in the hands of institutional investors. The top three institutional holders of CRSP stocks are: ARK INVESTMENT MANAGEMENT LLC with ownership of 8,457,320, which is approximately 30.449% of the companys market cap and around 1.30% of the total institutional ownership; CAPITAL INTERNATIONAL INVESTORS, holding 7,394,274 shares of the stock with an approximate value of $898.77 million in CRSP stocks shares; and NIKKO ASSET MANAGEMENT AMERICAS, INC., currently with $449.45 million in CRSP stock with ownership of nearly -0.385% of the companys market capitalization.
Positions in CRISPR Therapeutics AG stocks held by institutional investors increased at the end of October and at the time of the October reporting period, where 165 institutional holders increased their position in CRISPR Therapeutics AG [NASDAQ:CRSP] by around 12,811,732 shares. Additionally, 122 investors decreased positions by around 4,673,961 shares, while 56 investors held positions by with 29,914,080 shares. The mentioned changes placed institutional holdings at 47,399,773 shares, according to the latest SEC report filing. CRSP stock had 69 new institutional investments in for a total of 1,942,641 shares, while 36 institutional investors sold positions of 1,051,583 shares during the same period.
See more here:
CRISPR Therapeutics AG [CRSP] Revenue clocked in at $77.40 million, up 99.57% YTD: Whats Next? - The DBT News
- 'Incredible' gene-editing result in mice inspires plans to treat premature-aging syndrome in children - Science Magazine - January 9th, 2021
- CRISPR Therapeutics Is Still Looking Strong - RealMoney - RealMoney - January 9th, 2021
- Global CRISPR Technology Market Report 2020: COVID-19 Growth and Change - Market is Expected to Recover to Reach $1.55 Billion in 2023 - Forecast to... - January 9th, 2021
- What is the Market's View on Crispr Therapeutics AG (CRSP) Stock's Price and Volume Trends - InvestorsObserver - January 9th, 2021
- 5 questions facing gene therapy in 2021 - BioPharma Dive - January 9th, 2021
- CRISPR-based strategies in infectious disease diagnosis and therapy - DocWire News - January 9th, 2021
- Plant Breeding And CRISPR Plants Market Is Expected To Reach USD 21.78 Billion By 2027 | Top Companies- Bayer AG, KWS SAAT SE & Co. KGaA, DuPont,... - January 9th, 2021
- Where Does Crispr Therapeutics AG (CRSP) Stock Fall in the Biotechnology Field? - InvestorsObserver - January 9th, 2021
- CRISPR and CAS Gene Market 2021-2028 shooting revenue at US$ 7,603.8 Million with CRISPR Therapeutics, Mirus Bio, Caribou Biosciences, Editas... - January 9th, 2021
- The 221b Foundation Establishes Coalition to Control the Spread of COVID-19 in Nepal - Business Wire - January 9th, 2021
- Strategies and applications for CRISPRko, RNAi and beyond - SelectScience - January 9th, 2021
- TRIM26 is a critical host factor for HCV replication and contributes to host tropism - Science Advances - January 9th, 2021
- Four Predictions for the Future of Food in 2021 - The Spoon - January 9th, 2021
- Why CRISPR Therapeutics, Editas Medicine, and Intellia Therapeutics Stocks Are Sinking Today - The Motley Fool - January 2nd, 2021
- Should Crispr Therapeutics AG (CRSP) be in Your Portfolio? - InvestorsObserver - January 2nd, 2021
- Can CRISPR Save Florida Citrus? - AG INFORMATION NETWORK OF THE WEST - AGInfo Ag Information Network Of The West - January 2nd, 2021
- 2020: The year science took centre-stage - The Hindu - January 2nd, 2021
- 2020 was a tough year, but there is a silver lining - Boston Herald - January 2nd, 2021
- Pairing CRISPR with a smartphone camera, this COVID-19 test finds results in 30 minutes - FierceBiotech - December 12th, 2020
- New CRISPR-based COVID-19 test uses smartphone cameras to spot virus RNA - University of California - December 12th, 2020
- Is CRISPR Therapeutics Heading for $170? - The Motley Fool - December 12th, 2020
- Intellia Therapeutics Achieves Normal Human Alpha-1 Antitrypsin Protein Levels in Non-Human Primates Through Targeted Gene Insertion for the Treatment... - December 12th, 2020
- De-extinction: Why CRISPR gene editing might be the most revolutionary development in science ever - Genetic Literacy Project - December 12th, 2020
- How CRISPR could help us discover and treat rare cancers - ZME Science - December 12th, 2020
- ASH: CRISPR-Cas9 Gene Editing Promising in TDT, SCD - HealthDay News - December 12th, 2020
- Kevin Davies' 'Editing Humanity' explores the CRISPR revolution and the ethical dilemmas that await us - Genetic Literacy Project - December 12th, 2020
- ASH 2020: Gilead eyes new Yescarta indication, Vertex/CRISPR make headway in sickle cell and more - PMLiVE - December 12th, 2020
- CiBER-seq dissects genetic networks by quantitative CRISPRi profiling of expression phenotypes - Science Magazine - December 12th, 2020
- CRISPR Therapeutics to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference - Yahoo Finance - November 30th, 2020
- Global $6.7 Billion CRISPR Technology Market Opportunities to 2030: Cas9 And gRNA, Design Tool, Plasmid and Vector, Other Delivery System Products -... - November 30th, 2020
- Crispr And Crispr-Associated (Cas) Genes Market trends, Forecast Analysis, Key segmentation by type and application to 2026 - Cheshire Media - November 30th, 2020
- CRISPR And CRISPR-Associated (Cas) Genes Market Competitive Insights with Global Outlook 2020-2026| Caribou Biosciences, Addgene, CRISPR THERAPEUTICS... - November 30th, 2020
- CRISPR Genome Editing Market Statistics and Research Analysis Released in Latest Industry Report 2020 | Coronavirus-COVID19 Impact Analysis With Top... - November 30th, 2020
- CRISPR Genome Editing Market to Exhibit Impressive Growth of CAGR during the pe - News by aeresearch - November 30th, 2020
- Autism genes affect development of neurons and glia - Spectrum - November 30th, 2020
- CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy - Science Advances - November 20th, 2020
- Heres Why You Should Stay Invested In CRISPR Stock Despite The Recent 3x Rally - Forbes - November 20th, 2020
- CRISPR for Citrus Greening - AG INFORMATION NETWORK OF THE WEST - AGInfo Ag Information Network Of The West - November 20th, 2020
- CRISPR Therapeutics to Participate in the Jefferies Virtual London Healthcare Conference - Yahoo Finance - November 20th, 2020
- Viewpoint: Farming one of the 'most inefficient industries.' The CRISPR revolution could change that - Genetic Literacy Project - November 20th, 2020
- CRISPR-edited bananas immune to killer pathogens advance toward commercialization in Africa - Genetic Literacy Project - November 20th, 2020
- CRISPR Technology Market Forecast To 2026 And COVID-19 Impact Analysis - The Think Curiouser - November 20th, 2020
- Faster, Cheaper, Easier COVID-19 Testing - Powering the New Engineer - University of Florida - November 20th, 2020
- Seeing Real-Time Biological Interactions with Graphene Transistors - Clinical OMICs News - November 20th, 2020
- Crispr Technology Market to 2026: Report on Top Company Players, Industry Insights and Overview - PRnews Leader - November 20th, 2020
- Application and Product Portfolio Analysis During the forecasted period of CRISPR Technology Market - PRnews Leader - November 20th, 2020
- CRISPR Genome Editing Market Research Report- Opportunities & Challenges With Totally Different Segments, Forecast- 2026 - The Think Curiouser - November 3rd, 2020
- Latest News 2020: CRISPR Technology Market by Coronavirus-COVID19 Impact Analysis With Top Manufacturers Analysis | Top Players: Thermo Fisher... - November 3rd, 2020
- Global CRISPR And CRISPR-Associated (Cas) Genes Market Views: Taking A Nimble Approach To Explores Huge Growth In Near Future With Eminent Players -... - November 3rd, 2020
- 3D Culture Models with CRISPR Screens Reveal Hyperactive NRF2 as a Prerequisite for Spheroid Formation via Regulation of Proliferation and Ferroptosis... - November 3rd, 2020
- The Impact of the Coronavirus on the Global CRISPR and Cas Genes Market Fact.MR Study 2020 2026 - The Cloud Tribune - November 3rd, 2020
- CRISPR And CRISPR-Associated (Cas) Genes Market: Drivers, Restraints, Opportunities, and Threats (20192025) - Eurowire - October 31st, 2020
- CRISPR Can be a Solution to Address the COVID-19 Pandemic | Roots Analysis - The Think Curiouser - October 31st, 2020
- Picking up where GMOs left off: CRISPR leads the way to 'greener' food production in the 21st century - Genetic Literacy Project - October 31st, 2020
- CRISPR is going to reshape the future of probiotic genomes: Expert - NutraIngredients-usa.com - October 29th, 2020
- Did The Underlying Business Drive CRISPR Therapeutics' (NASDAQ:CRSP) Lovely 407% Share Price Gain? - Yahoo Finance - October 29th, 2020
- CRISPR Therapeutics Stock Falls 3.5% on Q3 Results - Motley Fool - October 29th, 2020
- Plant Breeding and CRISPR Plants Market Report 2026 Focuses on Top Companies, Research Methodology, Drivers and Opportunities - Eurowire - October 29th, 2020
- CRISPR pioneer: "Science is on the ballot" in 2020 - Axios - October 28th, 2020
- Fast, cheap, accurate: Researchers pin hopes on Nobel Prize-winning CRISPR technology to detect coronavirus - USA TODAY - October 28th, 2020
- Kara Swisher and Dr. Jennifer Doudna on CRISPR and Its Possibilities - The New York Times - October 28th, 2020
- CRISPR-Cas9: The gene editing tool that has revolutionized molecular biology - McGill Tribune - October 28th, 2020
- Is CRISPR gene therapy for rare Angelman Syndrome on the horizon? - Health Europa - October 28th, 2020
- Molecular Dynamics Reveals a DNA-Induced Dynamic Switch Triggering Activation of CRISPR-Cas12a - DocWire News - October 28th, 2020
- Is CRISPR Therapeutics Really Headed to $110? - Motley Fool - October 28th, 2020
- Investing in Genomics and CRISPR - Everything You Need to Know - Securities.io - October 28th, 2020
- Pac-Man meets genetics in new DNA editing that plays like the game - SYFY WIRE - October 28th, 2020
- CRISPR Technology Market SWOT Analysis, Latest Trends, By Top Key Players- Thermo Fisher Scientific Merck KGaA GenScript Integrated DNA Technologies... - October 28th, 2020
- Women in Science: Thoughts on the 2020 Nobel Prize in Chemistry - Loma Beat - October 28th, 2020
- CRISPR Technology Market Will Generate New Growth Opportunities in the upcoming year - Aerospace Journal - October 28th, 2020
- CRISPR and Cas Genes Market Insight | Strategic Industry Evolutionary Analysis Focus on Leading Key Players and Revenue Growth Analysis by Forecast To... - October 28th, 2020
- CRISPR Technology Market 2020: Potential growth, attractive valuation make it is a long-term investment | Know the COVID19 Impact | Top Players:... - October 28th, 2020
- 'CRISPR and Coronavirus': Hear From Nobel Winner Jennifer Doudna - UC Davis - October 22nd, 2020
- UPDATED: CRISPR Therapeutics gets a snapshot of off-the-shelf CAR-T success in B-cell malignancies marred by the death of a patient - Endpoints News - October 22nd, 2020
- Intellia to kick-start first single-course 'curative' CRISPR shot, as it hopes to beat rivals Alnylam, Ionis and Pfizer - FierceBiotech - October 22nd, 2020
- CRISPR has brought pig-to-human organ transplants to the cusp of reality - Genetic Literacy Project - October 22nd, 2020
- CRISPR Cas9 Industry Market Overview, Environmental Analysis and Forecast to 2025 - Express Journal - October 22nd, 2020
- Advances and concerns raised by Crispr-Cas 9, the genetic scissors - Pledge Times - October 22nd, 2020
- What is CRISPR, the gene editing technology that won the Chemistry Nobel prize? - Grain Central - October 22nd, 2020
- CRISPR Can be a Solution to Address the COVID-19 Pandemic | Roots Analysis - Eurowire - October 22nd, 2020